Carisma Therapeutics’ (CARM) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM) in a report released on Monday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

Several other equities research analysts have also commented on CARM. Baird R W lowered Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $10.00 to $1.00 in a research note on Thursday, December 12th. Finally, HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Carisma Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.94.

Carisma Therapeutics Price Performance

Carisma Therapeutics stock opened at $0.44 on Monday. Carisma Therapeutics has a 52 week low of $0.38 and a 52 week high of $2.77. The stock has a fifty day moving average of $0.68 and a 200-day moving average of $0.93. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market capitalization of $18.29 million, a P/E ratio of -0.28 and a beta of 1.44.

Carisma Therapeutics (NASDAQ:CARM) last issued its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The business had revenue of $3.39 million during the quarter. On average, sell-side analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Institutional Trading of Carisma Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC increased its position in shares of Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Carisma Therapeutics in the second quarter valued at $40,000. Finally, Wexford Capital LP grew its position in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares in the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.